Literature DB >> 11182838

Use of prescription weight loss pills among U.S. adults in 1996-1998.

L K Khan1, M K Serdula, B A Bowman, D F Williamson.   

Abstract

BACKGROUND: Pharmacotherapy is recommended for the treatment of obese persons with a body mass index of 30 kg/m(2) or higher or a body mass index of at least 27 kg/m(2) plus an obesity-related comorbid condition.
OBJECTIVE: To estimate the prevalence of use of prescription weight loss pills in the United States in 1996-1998.
DESIGN: 1998 Behavioral Risk Factor Surveillance System, a nationally representative telephone survey.
SETTING: United States. PARTICIPANTS: 139 779 adults 18 years of age and older. MEASUREMENTS: Self-reported pill use for 1996-1998, body mass index (current and before pill use), age, sex, and race or ethnicity.
RESULTS: The 2-year prevalence of pill use was 2.5% (95% CI, 2.1% to 2.9%), or 4.6 million U.S. adults. Use was higher in women than in men (4.0% vs. 0.9%, respectively) and highest among Hispanic respondents (3.2%). Of pill users, 25% were not overweight (body mass index < 27 kg/m(2) before using pills.
CONCLUSIONS: Nearly 5 million U.S. adults used prescription weight loss pills in 1996-1998. However, one quarter of users were not overweight, suggesting that weight loss pills may be inappropriately used, especially among women, white persons, and Hispanic persons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182838     DOI: 10.7326/0003-4819-134-4-200102200-00011

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Extracts from "Clinical Evidence". Obesity.

Authors:  D Arterburn; P H Noël
Journal:  BMJ       Date:  2001-06-09

Review 2.  Antiobesity drugs: current and future issues.

Authors:  M Ammar Hatahet; Nikhil V Dhurandhar
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 3.  Obesity in adults.

Authors:  David Delaet; Daniel Schauer
Journal:  BMJ Clin Evid       Date:  2011-03-17

Review 4.  New pharmacological treatments for the management of obesity.

Authors:  Ryan T Hurt; Jithinraj Edakkanambeth Varayil; Jon O Ebbert
Journal:  Curr Gastroenterol Rep       Date:  2014

5.  Quality of weight loss advice on internet forums.

Authors:  Kevin O Hwang; Kiran Farheen; Craig W Johnson; Eric J Thomas; Ann S Barnes; Elmer V Bernstam
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965

6.  Diet and physical activity behavior among users of prescription weight loss medications.

Authors:  Heidi Michels Blanck; Laura Kettel Khan; Mary K Serdula
Journal:  Int J Behav Nutr Phys Act       Date:  2004-12-23       Impact factor: 6.457

7.  Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals.

Authors:  Charles F Dahl; Marvin R Allen; Paul M Urie; Paul N Hopkins
Journal:  BMC Med       Date:  2008-11-06       Impact factor: 8.775

8.  Risk of valvular heart disease associated with use of fenfluramine.

Authors:  Paul N Hopkins; Gerald I Polukoff
Journal:  BMC Cardiovasc Disord       Date:  2003-06-11       Impact factor: 2.298

9.  The relationship between BMI and the prescription of anti-obesity medication according to social factors: a population cross sectional study.

Authors:  Lynsey Patterson; Frank Kee; Carmel Hughes; Dermot O'Reilly
Journal:  BMC Public Health       Date:  2014-01-28       Impact factor: 3.295

10.  The use of appetite suppressants among health sciences undergraduate students in Southern Brazil.

Authors:  Carlos Zubaran; Rubia Lazzaretti
Journal:  Einstein (Sao Paulo)       Date:  2013 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.